Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.885 USD | -1.28% | -11.24% | +9.29% |
Jun. 01 | Transcript : Iovance Biotherapeutics, Inc. - Special Call | |
May. 13 | Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained | MT |
Evolution of the average Target Price on Iovance Biotherapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Iovance Biotherapeutics, Inc.
Truist Securities | |
Piper Sandler | |
Wells Fargo Securities | |
Barclays | |
Goldman Sachs | |
Chardan Research | |
HC Wainwright | |
Stifel Nicolaus | |
Baird | |
Oppenheimer | |
JMP Securities | |
Guggenheim | |
Chardan | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- IOVA Stock
- Consensus Iovance Biotherapeutics, Inc.